Inferred Brain Cell-Type Shifts Accompany Schizophrenia and Bipolar Disorder and Differentially Correlate With Antipsychotic Drug Exposure

2021 ◽  
Vol 89 (9) ◽  
pp. S118-S119
Author(s):  
Anton Schulmann ◽  
Stefano Marenco ◽  
Nirmala Akula ◽  
Pavan Auluck ◽  
Barbara Lipska ◽  
...  
2020 ◽  
Author(s):  
Jinjin Tian ◽  
Jiebiao Wang ◽  
Kathryn Roeder

AbstractMotivationGene-gene co-expression networks (GCN) are of biological interest for the useful information they provide for understanding gene-gene interactions. The advent of single cell RNA-sequencing allows us to examine more subtle gene co-expression occurring within a cell type. Many imputation and denoising methods have been developed to deal with the technical challenges observed in single cell data; meanwhile, several simulators have been developed for benchmarking and assessing these methods. Most of these simulators, however, either do not incorporate gene co-expression or generate co-expression in an inconvenient manner.ResultsTherefore, with the focus on gene co-expression, we propose a new simulator, ESCO, which adopts the idea of the copula to impose gene co-expression, while preserving the highlights of available simulators, which perform well for simulation of gene expression marginally. Using ESCO, we assess the performance of imputation methods on GCN recovery and find that imputation generally helps GCN recovery when the data are not too sparse, and the ensemble imputation method works best among leading methods. In contrast, imputation fails to help in the presence of an excessive fraction of zero counts, where simple data aggregating methods are a better choice. These findings are further verified with mouse and human brain cell data.AvailabilityThe ESCO implementation is available as R package SplatterESCO (https://github.com/JINJINT/SplatterESCO)[email protected]


Cephalalgia ◽  
2018 ◽  
Vol 38 (13) ◽  
pp. 1976-1983 ◽  
Author(s):  
William Renthal

Background Migraine is a debilitating disorder characterized by severe headaches and associated neurological symptoms. A key challenge to understanding migraine has been the cellular complexity of the human brain and the multiple cell types implicated in its pathophysiology. The present study leverages recent advances in single-cell transcriptomics to localize the specific human brain cell types in which putative migraine susceptibility genes are expressed. Methods The cell-type specific expression of both familial and common migraine-associated genes was determined bioinformatically using data from 2,039 individual human brain cells across two published single-cell RNA sequencing datasets. Enrichment of migraine-associated genes was determined for each brain cell type. Results Analysis of single-brain cell RNA sequencing data from five major subtypes of cells in the human cortex (neurons, oligodendrocytes, astrocytes, microglia, and endothelial cells) indicates that over 40% of known migraine-associated genes are enriched in the expression profiles of a specific brain cell type. Further analysis of neuronal migraine-associated genes demonstrated that approximately 70% were significantly enriched in inhibitory neurons and 30% in excitatory neurons. Conclusions This study takes the next step in understanding the human brain cell types in which putative migraine susceptibility genes are expressed. Both familial and common migraine may arise from dysfunction of discrete cell types within the neurovascular unit, and localization of the affected cell type(s) in an individual patient may provide insight into to their susceptibility to migraine.


2021 ◽  
Vol 14 (2) ◽  
pp. 182-185
Author(s):  
Marcin Siwek

Quetiapine is an antipsychotic drug with proven efficacy in the treatment of schizophrenia and bipolar disorder as well as recurrent depression and generalized anxiety disorder. There is also evidence of the efficacy of quetiapine in other disorders dominated by affective and/or anxiety symptoms, for which treatment is not registered in Poland. The paper presents information useful in medical practice and presents descriptions of use cases.


1999 ◽  
Vol 46 (2) ◽  
pp. 161-172 ◽  
Author(s):  
Lynn D. Selemon ◽  
Michael S. Lidow ◽  
Patricia S. Goldman-Rakic

2002 ◽  
Vol 17 (6) ◽  
pp. 349-352 ◽  
Author(s):  
D. Becker ◽  
Y. Grinberg ◽  
A. Weizman ◽  
R. Mester

SummaryBackground.Flupenthixol is an antipsychotic drug with known mood-elevating properties. Its propensity to induce manic symptoms has not been investigated.Methods and results.We describe six patients, four with schizophrenia and two with bipolar disorder, in whom flupenthixol treatment was associated with emergence of manic symptoms.Conclusions.Patients treated with flupenthixol should be carefully monitored for the emergence of manic symptoms.


2017 ◽  
Vol 209 ◽  
pp. 86-92 ◽  
Author(s):  
Che-Sheng Chu ◽  
Po-Han Chou ◽  
Yi-Huei Chen ◽  
Min-Wei Huang ◽  
Min-Yen Hsu ◽  
...  

1996 ◽  
Vol 16 (7) ◽  
pp. 2275-2282 ◽  
Author(s):  
JM Fritschy ◽  
S Brandner ◽  
A Aguzzi ◽  
M Koedood ◽  
B Luscher ◽  
...  

Medical Care ◽  
1993 ◽  
Vol 31 (5) ◽  
pp. 432-444 ◽  
Author(s):  
RICHARD E. JOHNSON ◽  
BENTSON H. MCFARLAND

Sign in / Sign up

Export Citation Format

Share Document